Drugs / BC Pram Ins
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03512236 | Apr 2018 → Feb 2019 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2019-06-04 | Adocia | Results Adocia Announces Scientific Data Presentations at the American Diabetes Association® 79th Scientific Sessions adocia.com ↗
We are very pleased to share data showing that we replicate the postprandial effect of this association in a single injection of our coformulation of pramlintide and human insulin, potentially removing the burden of three additional daily injections. |
| 2018-09-05 | Adocia | Results Adocia announces positive topline results for the first clinical study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes adocia.com ↗
BC Pram Ins showed a significant 97% decrease in blood glucose excursion over the first two hours after the meal compared to Humalog® |
All press releases naming this drug 2 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BC Pram Ins | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03512236 ↗ |
| Known as | BioChaperone pramlintide human insulin | “simultaneous administrations of BioChaperone® pramlintide human insulin (BC Pram Ins) and placebo” NCT03512236 ↗ |
| Route | Subcutaneous | “Single subcutaneous injection of BC Pram Ins” NCT03512236 ↗ |